Genome-guided cancer treatment decision support
MH Guide identifies safe and effective therapies for cancer patients by analyzing the cancer’s molecular profile. It matches detected mutations to the world’s knowledge in the field of oncology and helps medical experts to create a patient-specific clinical report.
Finding safe and effective therapies for cancer patients
MH Guide is a treatment decision support software for oncologists, molecular pathologists and clinical laboratories. It translates complex genetic data from cancer samples into actionable clinical insights, helping physicans to find targeted therapies, immunotherapies, and clinical trails for their patients, personalized medicine becomes a reality.
Approved for clinical use
Registered as an IVD medical device in the EU, MH Guide is designed for clinical use.
Molecular Health has been CAP- and CLIA-certified since 2016, the first international bioinformatics dry laboratory to achieve this milestone.
Our compliance with rigorous international standards means you can rely on the results with confidence.
Reimbursement agreements are in place with major payers for pediatric and ovarian cancers, with negotiations in process for other cancer types.
World-class knowledge database
Medical professionals benefit in their daily practice from actionable clinical insights based on Molecular Health’s proprietary knowledge platform, Dataome. Dataome integrates expert-curated, up-to-date, and medically approved clinico-molecular variant interpretations (CVIs) based on scientific peer-reviewed literature, genome studies, and reference databases.